ZTS

Zoetis
NYSE

Real-time Quotes | Nasdaq Last Sale

137.66
+0.47
+0.34%
After Hours: 137.66 0 0.00% 18:19 07/02 EDT
OPEN
138.58
PREV CLOSE
137.19
HIGH
139.05
LOW
137.37
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
146.26
52 WEEK LOW
90.14
MARKET CAP
65.38B
P/E (TTM)
40.95
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZTS stock price target is 138.92 with a high estimate of 159.00 and a low estimate of 112.00.

EPS

ZTS News

More
Zoetis to Host Webcast and Conference Call on Second Quarter 2020 Financial Results
Zoetis will report second quarter 2020 financial results on Aug. 6, 2020.
Business Wire · 06/26 12:30
Meet the Pharma Company That Just Had a Bigger IPO Than Moderna's
MotleyFool.com · 06/23 10:51
Is It Safe to Buy Stocks Now?
MotleyFool.com · 06/23 04:00
3 Top Animal-Health Companies to Buy in June
MotleyFool.com · 06/19 11:13
Goldman Sachs has a 'World Winners' portfolio of global companies with superior growth prospects
Goldman Sachs identified a list of global stocks that offer growth opportunity for investors.
CNBC.com · 06/18 18:37
PreMarket Prep Stock Of The Day: Royalty Pharma
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upco
Benzinga · 06/18 16:37
Stocks making the biggest moves in the premarket: Lennar, T-Mobile US, Amazon, Eli Lilly & more
The stocks making the biggest moves in premarket trading include Lennar, T-Mobile US, Amazon, Eli Lilly, and more.
CNBC.com · 06/16 11:54
Wall Street Breakfast: It's All About The Fed
Seeking Alpha - Article · 06/16 11:04

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ZTS

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
More

Webull offers kinds of Zoetis Inc stock information, including NYSE:ZTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZTS stock methods without spending real money on the virtual paper trading platform.